Search

Displaying results 211 - 220 of 1901 in total
  1. Drug

    Domvanalimab

    go.drugbank.com/drugs/DB18848
    Investigational

    Domvanalimab is under investigation in clinical trial NCT05502237 (Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-small Cell Lung Cancer).

    Synonyms: Immunoglobulin g1 (236-alanine,237-alanine,de-c-terminal-lysine), anti-(human receptor tigit)(human-mus musculus monoclonal ab154 .gamma.1-chain), disulfide with human-mus musculus monoclonal ab154 .kappa
  2. Drug

    Inbakicept

    go.drugbank.com/drugs/DB16479
    Investigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without … Inbakicept is a dimeric human IL-15 receptor α (IL-15Rα) sushi domain/human IgG1 Fc fusion protein.

    Synonyms: INTERLEUKIN 15 RECEPTOR .ALPHA. CHAIN (HUMAN SUSHI DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN FC FRAGMENT), DIMER, INTERLEUKIN 15 RECEPTOR SUBUNIT ALPHA (HUMAN IL15R.ALPHA.) (1-65)-PEPTIDE (SUSHI DOMAIN-CONTAINING) FUSION PROTEIN WITH HUMAN IMMUNOGLOBULIN G1 FC FRAGMENT (232 C-TERMINAL RESIDUES) (66-297) (HOMO SAPIENS
  3. Drug

    NKX101

    go.drugbank.com/drugs/DB18131
    Investigational

    NKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.

    Synonyms: a fourth generation activating chimeric receptor (ACR) natural killer (NK) cell therapy engineered with an NKG2D ACR, OX40 costimulatory domain, CD3zeta signaling moiety, and membrane bound IL-15 (mb-IL15
  4. Drug

    Thrombin

    go.drugbank.com/drugs/DB11300
    ApprovedInvestigational

    Bovine thrombin however, is capable of causing fatal severe bleeding or thrombosis [FDA Label]. This thrombosis may result from the development of antibodies against bovine thrombin [FDA Label]. … Bleeding may result from the development of antibodies against bovine factor V [FDA Label].

  5. Drug

    Enapotamab vedotin

    go.drugbank.com/drugs/DB16156
    Investigational

    Enapotamab vedotin is under investigation in clinical trial NCT02988817 (Enapotamab Vedotin (Humax-axl-adc) Safety Study in Patients With Solid Tumors).

    Synonyms: Immunoglobulin g1, anti-(human growth factor receptor axl)(human humax-axl .gamma.1-chain), disulfide with human humax-axl .kappa.-chain, dimer tetrakis(thioether) with vedotin
  6. Drug

    Colestipol

    go.drugbank.com/drugs/DB00375
    Approved

    [FDA Label, F4555, F4567, L6262] … [FDA Label, F4555, F4567, L6262] The resultant lack of systemic exposure consequently means the medication generally demonstrates very few adverse effects inside the body.

  7. Drug

    Sitagliptin

    go.drugbank.com/drugs/DB01261
    ApprovedInvestigational

    Sitagliptin was granted FDA approval on October 16, 2006[L6061]. … The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255].

    Mixtures: Nra-sitagliptin/metformin, Nra-sitagliptin/metforminProducts: Nra-sitagliptin, Nra-sitagliptin Tablets
  8. Drug

    Zilovertamab

    go.drugbank.com/drugs/DB18403
    Investigational

    Synonyms: Immunoglobulin g1, anti-(human receptor tyrosine kinase ror-1) (human-mus musculus monoclonal uc-961 .gamma.1-chain), disulfide with human-mus musculus monoclonal uc-961 .kappa.-chain, dimer
  9. Drug

    AOC 1001

    go.drugbank.com/drugs/DB18620
    Investigational

    Delpacibart (AOC 1001) is being investigated in a global study for the treatment of Myotonic Dystrophy type 1 (DM1) in clinical trial NCT06411288

    Synonyms: Immunoglobulin G1 [233-alanine,234-alanine,327-arginine,de-446-lysine], anti-(human type 1 transferrin receptor) (human-Mus musculus clone AV05 γ1-chain), disulfide with human-Mus musculus clone AV05 κ-chain
  10. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism … Seladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. Seladelpar is a single enantiomer of the R-configuration.

    Synonyms: (4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)SULFANYL)-2-METHYLPHENOXY)ACETIC ACID PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR) AGONIST,ANTIHYPERLIPIDAEMIC